These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3245290)

  • 1. Blood group A substances are not present in currently available pneumococcal vaccine.
    Nalin DR; Morges W
    Vaccine; 1988 Dec; 6(6):469-70. PubMed ID: 3245290
    [No Abstract]   [Full Text] [Related]  

  • 2. Blood group antibodies induced by pneumococcal vaccine.
    Potter EV
    J Pediatr; 1982 May; 100(5):836-7. PubMed ID: 7069555
    [No Abstract]   [Full Text] [Related]  

  • 3. Reformulated Pneumovax available.
    Krakowshi FM; Santopolo AC
    Am Fam Physician; 1982 Jun; 25(6):50. PubMed ID: 7081010
    [No Abstract]   [Full Text] [Related]  

  • 4. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.
    Robbins JB; Austrian R; Lee CJ; Rastogi SC; Schiffman G; Henrichsen J; Mäkelä PH; Broome CV; Facklam RR; Tiesjema RH
    J Infect Dis; 1983 Dec; 148(6):1136-59. PubMed ID: 6361173
    [No Abstract]   [Full Text] [Related]  

  • 5. IgA, IgG and IgM anti-blood group A antibodies induced by pneumococcal vaccine.
    Koskela P; Nurmi T; Häiva VM
    Vaccine; 1988 Jun; 6(3):221-2. PubMed ID: 3420973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive effect of pneumococcal vaccine contaminated with blood-group-A-like substance.
    Nurmi T; Koskela P
    Lancet; 1988 Apr; 1(8588):771. PubMed ID: 2895302
    [No Abstract]   [Full Text] [Related]  

  • 7. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides.
    Robbins JB; Schneerson R
    Bull Eur Physiopathol Respir; 1983; 19(2):215-26. PubMed ID: 6347282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-group-A-like substances in pneumococcal vaccine.
    Croft SM; Jarrett MP; Snyder EL
    Ann Intern Med; 1982 Aug; 97(2):284. PubMed ID: 7103295
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-A isoagglutinins and pneumococcal vaccine.
    Noël A
    Lancet; 1981 Sep; 2(8248):687-8. PubMed ID: 6116059
    [No Abstract]   [Full Text] [Related]  

  • 10. Blood group substances in pneumococcal vaccine.
    Nalin DR; Morges W
    Lancet; 1988 Sep; 2(8612):695. PubMed ID: 2901561
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of stimulation of isohemagglutinin antibodies by immunization with group B streptococcal (type III) vaccine.
    Webb BJ; Kasper DL; Baker CJ
    J Pediatr; 1981 Dec; 99(6):918-20. PubMed ID: 7031212
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody response to group B streptococcus type III and AB blood group antigens induced by pneumococcal vaccine.
    Boyer KM; Theeravuthichai J; Vogel LC; Orlina A; Gotoff SP
    J Pediatr; 1981 Mar; 98(3):374-8. PubMed ID: 7009817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic protein contaminants in pneumococcal vaccines.
    Yu J; Briles DE; Englund JA; Hollingshead SK; Glezen WP; Nahm MH
    J Infect Dis; 2003 Mar; 187(6):1019-23. PubMed ID: 12660950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of responses to pneumococcal vaccine.
    Kline MW; Shearer WT
    Ann Allergy; 1993 Apr; 70(4):261. PubMed ID: 8466089
    [No Abstract]   [Full Text] [Related]  

  • 15. Blood-group-A-like substance in a preparation of pneumococcal vaccine.
    Siber GR; Ambrosino DM; Gorgone BC
    Ann Intern Med; 1982 May; 96(5):580-6. PubMed ID: 7073150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal vaccine response in human immunodeficiency virus-infected patients.
    Swiatlo E; Benton K; Briles DE
    J Infect Dis; 1996 Mar; 173(3):777-8. PubMed ID: 8627053
    [No Abstract]   [Full Text] [Related]  

  • 17. Type-specific antibody responses of volunteers immunized with 23-valent pneumococcal polysaccharide vaccine.
    Mufson MA; Hughey D; Lydick E
    J Infect Dis; 1985 Apr; 151(4):749-50. PubMed ID: 3973424
    [No Abstract]   [Full Text] [Related]  

  • 18. Revaccination of high-risk adults with pneumococcal polysaccharide vaccine.
    Nichol KL
    JAMA; 1999 Jan; 281(3):280-1. PubMed ID: 9918486
    [No Abstract]   [Full Text] [Related]  

  • 19. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.
    Anttila M; Eskola J; Ahman H; Käyhty H
    J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial of the protective role of polyvalent pneumococcal vaccine in sickle cell anaemia patients in Zambia.
    Chintu C; Gupta K; Osborne C; Masona JM
    Med J Zambia; 1983 Jul; 17(3):73-6. PubMed ID: 6679155
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.